Clinical Trial Update: A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC [Phase 1]

View source ↗

Summary

This Phase 1b trial evaluates PEGPH20 plus docetaxel in recurrent or metastatic non-small cell lung cancer; the study was terminated with results posted in 2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PEGPH20 (pegylated hyaluronidase)

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-02-08